Trial
NCT00647972
Fasting Study of Olanzapine Tablets 20 mg and Zyprexa® Tablets 20 mg
Phase ITERMINATEDSAFETYConfidence: HIGH
Sponsor
Mylan Pharmaceuticals Inc
Collaborators
—
Condition
Healthy
Intervention
Olanzapine Tablets 20 mg
Why stopped
during Period 1 due to numerous orthostatic AEs that occurred. Subsequently, RLD was reduced to 5 mg due to safety concerns.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2024-04-23